Table 7.

Major adverse reactions associated with KIs are listed. Incidence is from across all FDA indications of each KI using the highest percent reported and landmark studies that lead to KI approval by FDA. Percent may be different from smaller phase 2 studies.

Kinase Inhibitor	Black Box Warning	Fatal Hepatic Failure	Grade 3/4 AST/ALT	Grade 3/4 Total Bilirubin	Any Grade QT Prolongation	Grade 3 QT Prolongation	Tors ades
Axitinib	None		<1%
Bosutinib	None		7%	1%	<10%	0.2%
Cabozantinib	Perforation, fistula, or hemorrhage		6%			None
Crizotinib	None		7%		3.5%	1.3%
Dasatinib	None		<1%	1%		1%
Erlotinib	None		1% NSCLC, 13%) Pancreatic	<1% NSCLC 10% Pancreatic
Gefitinib	None
Imatinib	None		3%	1.1%
Lapatinib	Hepatotoxicity	Few deaths	5%	4%
Nilotinib	QT prologation, torsades		4%	4%	4.1%	<1%
Pazopanib	Hepatotoxicity	0.2%	12%	3%		2%	<1%
Regorafenib	Hepatotoxicity	0.3%-0.8%	6%	13%
Ruxolitinib	None		1.3%
Sorafenib	None				Rare
Sunitinib	Hepatotoxicity	0.3%	5%	1%			<0.1 %
Vandetanib	QT prologation, torsades		2%	0%	14%	8%	Few cases
Vemurafenib	None		2.8%	1.9%
Vismodegib	Embryo-fetal death or severe birth defects
Ponatinib	Arterial thrombosis Hepatotoxicity	3 fatal cases	8%	1%	Mostly ≤20ms changes

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NSCLC, non-small cell lung carcinoma.